Navigation Links
Frost & Sullivan Market Study Gives 'Thumbs Up' for Pepex™ Trio™ One-Click™ Blood Glucose Meter
Date:12/21/2010

ST. LOUIS, Dec. 21, 2010 /PRNewswire/ -- Research firm Frost & Sullivan, a leading international healthcare consulting company, released a market study analyzing and estimating the demand for Pepex Biomedical Inc.'s new biosensor technology for blood glucose monitoring for diabetes sufferers worldwide.  The researchers interviewed diagnosed diabetics, diabetes educators, endocrinologists, and manufacturers of biosensors, blood glucose meters, or other clinical diagnostic or patient monitoring equipment suppliers for the study.  The Frost & Sullivan report concluded that the Pepex Trio technology has the "potential as a new standard for measuring blood glucose levels."

The analysts noted three areas of opportunity for innovation in their review of diabetes monitoring:

  • Improved meter accuracy and reliability to assure proper insulin dosages
  • Ease of use for improved testing compliance
  • Reduction in the cost of the commonly used single-use disposable test strips

Additional needs are the users' desire for improved meter convenience, minimizing operator technique, increased speed of results and a compact meter size because many diabetics are required to carry their meters for around-the-clock testing.

Frost & Sullivan commented that, "Pepex is well-positioned to capitalize on (these needs) with a truly novel approach that may improve accuracy of readings and also provide other benefits to patients in terms of ease-of-use and lower costs."  This is important because, "Recently, the FDA petitioned the International Organization for Standardization to change the allowable error rate for BGMs, currently at plus or minus 20 percent, to be more accurate.  The wide error rate has been a concern for many years as it can leave patients vulnerable to hypo and hyperglycemic episodes." The American Association of Clinical Endocrinologists formally asked the FDA to act on this issue, "Because of the highly variable quality of the meters and the glucose testing strips in widespread use, the safety of our patients who depend upon those meters is threatened."  

Pepex CEO, Steve Collins, offered, "We expect the company's game-changing biosensor technology, packaged within our easy to use, one-button blood glucose meter, to deliver the accuracy required to meet or exceed future FDA standards. Trio's unique sensor design minimizes operator technique which can lead to user errors and affect the accuracy of glucose readings."

Approximately 60% of diabetics interviewed for the research said they would definitely replace their current meters with the Pepex Trio for the new technology's accuracy and convenience benefits.  As a result, Frost & Sullivan estimates that Pepex has a significant 5 year revenue opportunity, in the blood glucose monitoring market segment.  In addition, the breakthrough electrochemical biosensors are applicable to a variety of additional markets outside of glucose.

Pepex is a privately held a medical device company specializing in the development, manufacturing, and marketing of disposable, miniaturized electrochemical biosensors.  The company protects its market opportunities with 64 patents which encompass a broad spectrum of proprietary technology including: sensor chemistry and architecture, wireless sensor communications and laser welding manufacturing processes.  Pepex biosensors are the heart of a pipeline of life altering products for medical diagnostics and intervention.  The company is led by a team of business and scientific professionals experienced in the biomedical field and populated by a development staff with a successful track record of delivering next generation biomedical devices to market.  For more information, please visit www.pepex.com.  

For more information about this topic, or to schedule an interview with Joseph Driver, please call Andrea Skov at 408.888.3338 or e-mail Andrea at andrea.skov@pepex.com


'/>"/>
SOURCE Pepex Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
3. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
4. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
5. Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
6. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
7. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
8. Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough
11. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... ... Today, the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 ... in 2017. Clinicians who participate in APMs are paid for the quality of care ... effort to build a system that delivers better care and one in which clinicians ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the ... needs of over 30 million. Many interviews with Dr. Carol Francis at the Los ... were suppose to prioritize. Interviews provided below. , Among those present was ...
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have to clear ... when clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s ... Safety Commission for the proper use of snow blowers:, , When ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... engineers, and scientists from around the world, announces the launch of its newly ... and easy portal to research breakthroughs and trending news, vital information on upcoming ...
(Date:1/19/2017)... Melville, New York (PRWEB) , ... January 19, ... ... state–of-the-art high definition dynamic telemedicine solutions, has recently unveiled impressive transportable capabilities with ... this newly designed product is an extension to RMT technology that delivers HD, ...
Breaking Medicine News(10 mins):